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Measurement of sex hormones in urine
A B S T R A C T
Objective: We aimed to establish correlations for the levels of follicle-stimulating hormone (FSH), estrone (E1)
and estradiol (E2) between urine and serum in premenopausal and postmenopausal women using im-
munoassays.
Methods: In this study of 92 women (61 postmenopausal, 31 premenopausal), both urine and blood specimens
were collected on the same day and stored at 4 °C for analysis by chemiluminescent immunoassay, radio-
immunoassay and/or electrochemiluminescent immunoassay.
Results: There were correlations in the levels of FSH, E1 and E2 between urine and serum in both post-
menopausal (r=0.96 for FSH, r=0.91 for E1, r=0.80 for E2) and premenopausal (r=0.98 for FSH, r=0.92
for E1, r=0.90 for E2) women. It is indicated that the correlations were stronger in the premenopausal group
compared with the postmenopausal group, especially for FSH.
Conclusion: The levels of FSH, E1 and E2 in urine correlated with those in the serum in premenopausal and
postmenopausal women. Urine samples could be used instead of serum samples to measure hormone levels,
which would reduce the difficulty of conducting large survey studies.
1. Introduction
Follicle-stimulating hormone (FSH), one of the gonadotropic hor-
mones, is released by the pituitary gland into the bloodstream. The
most important functions of FSH are to develop premature follicles in
the ovary and promote the secretion of estrogens. The two forms of
estrogen that are important indicators of menopausal status are estra-
diol (E2) and estrone (E1) [1]. As menopause progresses, the levels of
E2 decrease significantly and remain low, whereas the levels of FSH
increase and remain high [2,3]. According to one report, the trajectory
of FSH in postmenopausal women can be divided into three stages [4],
which could be an important indicator for conditions that are affected
by endogenous estrogen such as cardiovascular disease [5,6]. For ex-
ample, higher FSH levels were associated with an increased frequency
of hot flashes and night sweats [7], an increased progression of
asymptomatic atherosclerosis in middle-aged women [8] and a lower
prevalence of depression and depressive symptoms [9]. FSH was shown
to cause an increase in the circulating low-density-lipoprotein (LDL)
cholesterol levels by reducing the LDL receptor level [10]. However,
lower FSH levels were significantly associated with prediabetes and
diabetes [11] and negatively associated with non-alcoholic fatty liver
disease in women over 55 years of age [12]. Additionally, the prob-
ability of metabolic syndrome was two times higher when the FSH level
increased or decreased by one standard deviation [13]. Therefore, it is
important that we have a clear picture of the expression patterns of
FSH, E1 and E2 in the premenopausal and postmenopausal periods,
especially the postmenopausal FSH level.
Because these hormones are often measured using serum, the po-
tential for large-scale survey studies has been limited by costs and the
requirement of facilities such as hospitals that employ personnel who
are permitted to collect blood. Urine sampling, however, offers a non-
invasive collection method for study participants. In previous reports,
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the correlation between serum and urinary FSH was examined using
radioimmunoassay (RIA) or sandwich immunoenzymometric assays
(IEMAs), but only in specimens from premenopausal women [14,15].
With the cooperation of participants from the Gunma Nurses' Health
Study (GNHS) [16] and the Japan Nurses' Health Study (JNHS) [17],
we measured FSH, E1 and E2 levels in urine and blood samples from
premenopausal and postmenopausal women using three different im-
munoassays. Our aim was to establish the correlations in the levels of
FSH, E1 and E2 between urine and serum in premenopausal and post-
menopausal women.
2. Material and methods
2.1. Samples
This study enrolled 92 women (61 postmenopausal and 31 pre-
menopausal) who agreed to participate in this research and were
among the original participants of the GNHS and the JNHS, excluding
one woman whose urine sample volume was too small to detect sex
hormones. GNHS is an ongoing cohort study of 699 female nurses aged
20 and over that was initiated in 1999 [16]. JNHS is also an ongoing
cohort study that was established in 2001, and the participants con-
sisted of female nurses in Japan. Participants were recruited from 2001
to 2007; a total of 15,019 women responded to the baseline survey and
provided written informed consent to be followed up. Women with a
duration of< 1 year from their last menstrual period were defined as
premenopausal women, and those whose menstrual periods had ceased
for> 1 year were defined as postmenopausal. All samples were col-
lected on November 24, 2018, February 6, 2019, February 13, 2019,
and February 23, 2019. The ethics committee of Gunma University
reviewed and approved the study.
2.2. Urine and serum assays
Blood samples were collected in plain tubes that included coagu-
lation activators (Terumo, Tokyo, Japan) followed by centrifugation at
1720g for 10min; serum was collected and stored at 4 °C until the assay
was performed within 48 h after sample collection. Urine specimens
were collected in the morning on the same day as blood collection.
Urine specimens were subjected to centrifugation at 430g for 10min;
supernatants were collected and stored at 4 °C until the assay was
performed, which was within 48 h after the sample collection. Urinary
and serum FSH levels were measured by chemiluminescent im-
munoassay (CLIA) [18], urine and serum E1 and urine E2 levels were
measured by radioimmunoassay (RIA) [19] and serum E2 levels were
also measured by electrochemiluminescent immunoassay (ECLIA)
[20–22]. All measurements were performed by SRL, Inc. (Tokyo,
Japan). The creatinine-corrected urinary FSH, E1 and E2 were calcu-
lated to indicate the excretion amount per 1 g of urinary creatinine (Cr),
assuming that 1 g of urinary Cr is discharged per day.
2.3. Data analysis
We examined the correlations between FSH, E1 and E2 in urine and
serum using the Pearson product–moment correlation coefficient in a
linear regression model without an intercept. The limits of detection
(LODs) for serum E2 and urine E2 were 5.0 ng/L and 0.20mg/L, re-
spectively. Women for whom no E2 was detected were assigned to the
E2 value of the LODs/2 (serum, 2.5 ng/L; urine, 0.10mg/L). P < .05
was considered statistically significant. We used SAS 9.4 for Windows
for statistical analysis (SAS Institute Inc., Cary, NC, USA).
3. Results
The levels of FSH, E1 and E2 in postmenopausal and premenopausal
women are shown in Table 1. Serum E1 and E2 levels were higher (E1;
p= .0001, E2; p= .0002) while the serum FSH levels were lower
(p < .0001) in premenopausal women compared with postmenopausal
women. The urinary measurements of these hormones showed similar
tendencies.
There were significant correlations between the urine and serum
levels of all three hormones in postmenopausal women: FSH (r=0.96,
p < .0001), E1 (r=0.91, p < .0001) and E2 (r=0.80, p < .0001)
(Fig. 1). In premenopausal women, the positive correlations between
the urine and serum levels of E1, E2 and FSH were even stronger:
(r=0.98, p < .0001), E1 (r=0.92, p < .0001) and E2 (r=0.90,
p < .0001) (Fig. 1).
4. Discussion
In this study, we showed that the correlations in the relative con-
centrations of FSH, E1 and E2 between urine and serum were valid in
both premenopausal and postmenopausal women. There was a parti-
cularly strong correlation between serum and urine FSH in pre-
menopausal women (r= 0.98), which is consistent with a previous
report [23]. In addition, the correlations in E1 and E2 between serum
and urine in premenopausal women were within the reference values
despite the fact that spot urine samples were used for the analysis (E1:
1.00–8.00 μg/day; E2: 0.50–5.00 μg/day). In the clinical setting, RIA is
typically performed using 24-h urine collection, and this process is
considered to be complex because the compounds need to be extracted
from the urine specimens. However, in this study we were able to ob-
tain significant results using a simplified sample preparation of early
morning urine, which is considered to be suitable for analysis in large
cohorts. Previous studies measured the correlation between serum and
urinary FSH in premenopausal specimens [14,15], but there are few
reports that mention the analysis of this hormone in postmenopausal
women. The Study of Women's Health Across the Nation (SWAN)
identified three trajectories of changes in FSH during the menopausal
transition: low, high and medium rise patterns. After the final men-
strual period, FSH continued changing slightly, but leveled off. The
approximate plateau values for the FSH trajectory groups were 40 IU/L
for the low group, 85 IU/L for the medium group and 120 IU/L for the
high group [4]. Because strong correlations were found between blood
and urinary excretion levels of FSH in this study, we calculated the
urinary excretion of FSH corresponding to the FSH value for each of the
SWAN group categories. The urinary excretion of the low FSH group
was 61.1 IU/g-Cr, the medium FSH group was 129.7 IU/g-Cr and the
high FSH group was 183.2 IU/g-Cr (data not shown). These results in-
dicate that the measurement of even just one time point of FSH in urine
could be used to analyze FSH levels in postmenopausal women. We
clarified the correlation between urine and serum not only for FSH but
also for E1 and E2, using samples from postmenopausal women. These
results indicate that urine samples could be used to determine the re-
lative hormones level within a population and thereby support clinical
and epidemiological studies that are conducted in perimenopausal and
postmenopausal women.
A limitation of this study is that serum FSH, E1 and E2 values were
indicative of serum levels at the time of measurement, while urinary
FSH, E1 and E2 values reflected urinary excretion over a certain time
period.
In conclusion, we showed that the urinary measurements of FSH, E1
and E2 levels were similar to those of serum in both postmenopausal as
well as premenopausal women. Before this study, the correlations for
FSH levels between urine and serum in premenopausal and post-
menopausal women were not well established. Using the CLIA method,
this study revealed a strong correlation for FSH between urine and
serum. The use of urine specimens could make it possible to determine
the levels of FSH, E1 and E2 without undue burden on the study par-
ticipants, and contribute to the establishment of large-scale surveys.
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